REZDIFFRAREZDIFFRAREZDIFFRA

The FDA accredited REZDIFFRA based upon proof of efficacy from a scientific demo, Trial 1, of 888 patients who experienced a liver biopsy exhibiting inflammation resulting from NASH with average or Innovative liver scarring, but not with cirrhosis of the liver.The Rezdiffra prescribing data won't incorporate a liver biopsy necessity for analysis. T